CEL-SCI Corporation logo
CEL-SCI Corporation CVM
$ 3.44 -6.01%

Quarterly report 2025-Q4
added 02-17-2026

report update icon

CEL-SCI Corporation Gross Profit 2011-2026 | CVM

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit CEL-SCI Corporation

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - - - - - - - 255 K 956 K

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
956 K 255 K 605 K

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
625 M $ 221.88 -0.87 % $ 5 B danmarkDanmark
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Pharming Group N.V. Pharming Group N.V.
PHAR
113 M $ 15.36 -0.71 % $ 7.59 B niderlandNiderland
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
5.51 M - 2.54 % $ 160 B franceFrance
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
3 K $ 1.21 -3.97 % $ 71.5 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
4.73 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
102 K - -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
39.2 M - -0.23 % $ 916 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-32.3 K - 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Assembly Biosciences Assembly Biosciences
ASMB
79.1 K $ 28.46 3.45 % $ 319 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
2.32 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.27 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
90 K - -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
90 K - - $ 7.46 M israelIsrael
BioDelivery Sciences International BioDelivery Sciences International
BDSI
14 M - -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
4.67 B - 0.49 % $ 251 B cayman-islandsCayman-islands
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
1.34 B $ 54.13 -1.64 % $ 10.4 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
282 K $ 10.98 -4.52 % $ 452 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
64.9 M - - $ 3.74 B usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
63.5 M $ 2.09 -0.95 % $ 195 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
339 M $ 1.52 -5.59 % $ 178 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
1.07 - - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
123 M - -7.23 % $ 13 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-10.6 M - - $ 867 M germanyGermany
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
3.94 M $ 8.6 -3.8 % $ 115 M usaUSA
Curis Curis
CRIS
9.5 M $ 0.77 1.89 % $ 4.86 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
37.7 M $ 3.34 -4.02 % $ 116 M franceFrance